Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company based in Michigan, has announced the appointment of two individuals of Indian American descent to key leadership roles. Dr. Ash Jayagopal has been named the chief scientific and development officer, while Nirav Jhaveri assumes the position of chief financial officer, according to a statement from the company.
Dr. Jayagopal expressed enthusiasm about joining Ocuphire, citing the company’s successful track record in drug development and execution. He emphasized the significance of Ocuphire’s current phase, particularly in advancing APX3330 through clinical development for diabetic retinopathy treatment. Similarly, Jhaveri conveyed his excitement about joining a company with the potential to become a leader in ophthalmology drug development, highlighting Ocuphire’s dedication to addressing unmet needs in ophthalmic diseases.
George Magrath, the CEO of Ocuphire, emphasized the importance of Jayagopal and Jhaveri’s roles in advancing the company’s portfolio, especially the phase 3 program for diabetic retinopathy treatment. He expressed eagerness to collaborate with the newly appointed leaders in addressing significant medical needs through innovative science.
Dr. Jayagopal brings over 15 years of experience in bio-engineering, leading research teams in therapeutic research and development, drug delivery platforms, and biomarkers for retinal diseases. His previous roles include positions at Opus Genetics, Kodiak Sciences, and Roche. Additionally, he is involved in various professional associations and serves on advisory councils and editorial boards in the field of ophthalmology.
Jhaveri contributes over 20 years of experience in valuation, business development, and capital markets to Ocuphire. Prior to joining the company, he held positions at Insilico Medicine, Journey Medical Corporation, and Fortress Biotech, as well as roles in equity research and investment banking. He holds an MBA from New York University’s Stern School of Business and a bachelor’s degree in chemistry and economics from the University of Pennsylvania.
